These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24664166)

  • 21. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.
    Lin J; Bettin P; Lee JK; Ho JK; Sadiq SA
    J Neuroimmunol; 2013 Aug; 261(1-2):123-8. PubMed ID: 23800458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
    Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease-modifying drugs for multiple sclerosis and JC virus expression.
    Miller CS; Houff SA; Hopper J; Danaher RJ; Gurwell JA; Lin Y; Vega N; Berger JR
    J Neurovirol; 2012 Oct; 18(5):411-5. PubMed ID: 22585288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
    Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
    Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
    Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-JC virus seroprevalence in a Finnish MS cohort.
    Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
    Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
    Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Saure C; Warnke C; Zohren F; Schroeder T; Bruns I; Cadeddu RP; Weigelt C; Fischer U; Kobbe G; Hartung HP; Adams O; Kieseier BC; Haas R
    Arch Neurol; 2011 Nov; 68(11):1428-31. PubMed ID: 22084125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
    N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-126: a novel route for natalizumab action?
    Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL
    Mult Scler; 2014 Sep; 20(10):1363-70. PubMed ID: 24598267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.